GenScript Biotech Corporation is a global biotechnology group. GenScript’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services.

GenScript currently has more than 3000 employees globally, 33% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 70 patents and over 200 patent applications. As of January 2019, GenScript's products and services have been cited by 36,500 scientific papers worldwide.

GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

For more information, please visit:

The International Vaccine Institute (IVI) is a nonprofit International Organization established in 1997 as an initiative of the United Nations Development Programme (UNDP). We are among the few organizations in the world dedicated to vaccines and vaccination for global health.

Our mission: Discover, develop, and deliver safe, effective, and affordable vaccines for global public health.

IVI is headquartered in Seoul, Republic of Korea, as our host country. The Republic of Korea, Sweden, and the World Health Organization (WHO) are among the 36 signatories to our international treaty.

Our approach is based on three components:

  1. Research – vaccine R&D, translational and field research
  2. Partnerships – product development partnerships, international research consortia, and networks
  3. Capacity-building – training, technical assistance, and technology transfers

DBT/Wellcome Trust India Alliance (India Alliance) is an independent, dynamic public charity that funds research in health and biomedical sciences in India. India Alliance invests in transformative ideas and supportive research ecosystems to advance discovery and innovation to improve health and well-being. India Alliance stands for diversity, inclusivity, and transparency in science and works to facilitate the engagement of science with society.

India Alliance is funded by the Department of Biotechnology (DBT), the Government of India, and the Wellcome Trust, United Kingdom.

For 10 years, India Alliance has enabled high-quality, internationally competent biomedical research in India. Moving ahead, India Alliance is now set on a path to advance discovery and innovation to improve health in India. Its strategic plan is directed to-

1. Invest in basic biomedical, clinical, and public health research to tackle health challenges
2. Strengthen India’s research ecosystem to drive discovery and innovation
3. Engage with stakeholders to improve health for all

The Department of Biotechnology (DBT), under the Ministry of Science and Technology, Government of India, has been instrumental in the development of the field of modern biology and biotechnology in India. DBT with its intimate involvement with the nation’s effort to build capacity in human resources has greatly strengthened India Alliance’s capacity.

The Indian Practitioner is a monthly journal dedicated to Medicine, Surgery, and Public Health, which was established in 1947. The Indian Practitioner has on its editorial board highly experienced doctors in various aspects of medicine which ensure qualitative medical articles and features. The journal covers the entire spectrum of medicine and medical establishments which include private & govern­ment hospitals and clinics, private practitioners, physicians & surgeons, medical directors of pharma companies, and medical institutes/universities.

Asia-Pacific Biotech News (APBN) is a monthly science and technology magazine published by World Scientific Publishing, one of the leading scientific publishers in the world. APBN is available both in print and online. APBN’s readership reaches out to various professionals in the field of which include scientists, researchers, industry experts, and biotech investors. With the aim of bringing up–to–date news and advancements in science and technology within the Asia – Pacific region, APBN strives to achieve excellence and impartiality in science communication.

To create a community of informed readers, well-versed in the topics of science and technology and how it impacts the world around them.

To provide accurate, objective, and sincere reporting for research and industrial developments in the field of science and technology.

Don't Miss Out on Vaccines World Summit 2021

Speaking Opportunities

Pavithra Selvam
Conference Producer

Registration & Media

Rima Karan
Marketing Executive

Sponsorship & Exhibition

Ana Laxamana
Business Development Manager
Open chat
Come chat with us!
Hello! How can I help you?

Kindly fill in your details below to receive a copy of the Preliminary Program.
Thank you for your interest and cooperation!

    Products of Interest*
    Blood & Plasma ProductsAntibody TherapeuticsCell TherapyGene TherapyProtein TherapeuticsViral VaccinesImmunotherapeuticsOther BiologicsNon-biologicsMedical DeviceNone of the above

    Subscribe to our mailing list

    Kindly fill in the form below to receive the Sponsorship Prospectus by email.
    Thank you for your interest and cooperation!

      Products of Interest*
      Blood & Plasma ProductsAntibody TherapeuticsCell TherapyGene TherapyProtein TherapeuticsViral VaccinesImmunotherapeuticsOther BiologicsNon-biologicsMedical DeviceNone of the above

      Subscribe to our mailing list

      Non-Singapore Companies, kindly visit the registration page here.
      Singapore Companies, kindly visit the registration page here.